Shares of AbbVie, Eli Lilly and Gilead Sciences closed near record highs
$LLY
Price history, market instrument context, member research, and related headlines in one place.
LLY key statistics
NYSEUSD
52-week range
$783.8592%$1,292.65
Latest session $1,230.74–$1,275.88Eli Lilly and Company (LLY) is a stock instrument quoted on NYSE in USD. The most recently published price is $1,251.61, up $42.87 (3.55%) from the previous close of $1,208.74. It has traded between $1,230.74 and $1,275.88 in the latest session. Over the past year it has ranged from $783.85 to $1,292.65, leaving it in the upper quarter of its 52-week range (92%). Reported volume for the session was 3.7M. Figures are the latest published by the exchange feed and are not a recommendation.
Primary market bars from Yahoo Finance · Extended-hours prints appear when supplied by the venue · Interactive charts powered by TradingView Lightweight Charts™ · Not a recommendation
Source-linked intelligence
Related news
Eli Lilly and Novo are developing new amylin drugs that serve as another biological lever to pull in treating obesity and diabetes.
Every weekday, the Investing Club releases the Homestretch; an actionable afternoon update just in time for the last hour of trading.
Eli Lilly and Company (LLY)’s Weight-Loss Pill Just Won Its First Race in Europe. Novo Nordisk A/S (NVO) Still Has a Head Start — See source for full details.
Can Veeva Systems Inc. (VEEV)’s AI Platform Keep Pace With Eli Lilly and Company (LLY)’s Explosive Growth — See source for full details.
Eli Lilly and Company (LLY) vs. Novo Nordisk A/S (NVO): Is Lilly Pulling Ahead in the $100 Billion Obesity Market? — See source for full details.
As Lilly widens its lead in the obesity race, Novo is still racing to win back market share and restore investor confidence in its pipeline.
Loading $LLY research…